Supplementary Table 1.
Included, and excluded studies.
| Clinical outcomes and biomarkers | Studies were identified and screened [n] | Studies were excluded according to title, abstract or full text [n] | Studies were included [n] |
|---|---|---|---|
| Fibrinogen | 315 | 275 | 40 approved articles with totally 58 enrolled data for meta-analysis |
| D-dimer | 238 | 121 | 30 approved articles with totally 40 enrolled data for meta-analysis |
| PF1–2 | 86 | 79 | 7 approved articles with totally 9 enrolled data for meta-analysis |
| AT-III | 98 | 94 | 4 approved articles with totally 6 enrolled data for meta-analysis |
| TAT | 127 | 120 | 7 approved articles with totally 8 enrolled data for meta-analysis |
| t-PA | 437 | 426 | 11 approved articles with totally 14 enrolled data for meta-analysis |
| PAI | 91 | 80 | 11 approved articles with totally 15 enrolled data for meta-analysis |
| Alpha-2 antiplasmin | 18 | 18 | – |
| Fibrinopeptide-A | 21 | 18 | 3 approved articles with totally 4 enrolled data for meta-analysis |
| u-PA | 29 | 29 | – |
| Plasmin-antiplasmin | 22 | 21 | 1 approved articles with |
| vWF | 185 | 21 approved articles with totally 32 enrolled data for meta-analysis | |
| sTM | 37 | 31 | 6 approved articles with totally 7 enrolled data for meta-analysis |